Dual‐Target ROS‐Driven Spatiotemporal Senolysis for Vascular Repair and Immune Microenvironment Reprogramming in the Treatment of Ocular Fundus Neovascularization
Advanced Science · 2026
DOI: 10.1002/advs.202523495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yali Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, National Clinical Research Center for Eye Di…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Choroidal Neovascularization, Retinal Neovascularization, Cellular Senescence. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Science Foundation of China, National Major Science and Technology Projects of China, Key Technologies Research and Development Program.
Abstract (Originalsprache)
Ocular fundus neovascularization (OFN) is a leading cause of irreversible vision loss. Conventional antivascular endothelial growth factor (anti‐VEGF) therapies indiscriminately suppress pathological and reparative angiogenesis and fail to correct the senescence‐ and inflammation‐driven microenvironment that sustains disease progression. Senescent endothelial cells (ECs) form the structural scaffold of pathological vessels, while neighboring senescent microglia exacerbate inflammatory signaling, together deteriorating the reactive oxygen species (ROS)‐rich vascular‐immune microenvironment. Here, we develop an injectable ROS‐responsive senolytic hydrogel (PCC1/PHCF‐Gel) that enables lesion‐activated, sustained intraocular release of procyanidin C1 (PCC1), overcoming rapid clearance, oxidative degradation, and poor lesion retention associated with free PCC1. In oxygen‐induced retinopathy and choroidal neovascularization models, PCC1/PHCF‐Gel markedly reduces retinal senescence, suppresses pathological neovascularization, and restores neuroretinal function, outperforming symptom‐directed therapies anti‐VEGF therapy. Single‐cell RNA sequencing reveals selective elimination of two pathogenic senescent cell subpopulations—CXCR4 + ECs and IFITM3 + microglia—thereby disrupting the reinforcing cycle of vascular and immune senescence and promoting reparative vascular regeneration. These findings establish a multifunctional, spatiotemporally controlled therapeutic paradigm and highlight PCC1/PHCF‐Gel as a promising translational strategy for the precision treatment of OFN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, National Clinical Research Center for Eye Diseases, Shanghai Clinical Research Center for Eye Diseases, Shanghai K…
- Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Xun Xu
Förderung
- the National Science Foundation of China
- National Major Science and Technology Projects of China
- Key Technologies Research and Development Program
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y., Chen, T., Liu, P., Lv, K., Wang, Y., Wang, X., Fang, J., Chen, C., Wang, Z., Wei, F., & Xu, X. (2026). Dual‐Target ROS‐Driven Spatiotemporal Senolysis for Vascular Repair and Immune Microenvironment Reprogramming in the Treatment of Ocular Fundus Neovascularization. Advanced Science. https://doi.org/10.1002/advs.202523495
Vancouver
Zhou Y, Chen T, Liu P, Lv K, Wang Y, Wang X, et al. Dual‐Target ROS‐Driven Spatiotemporal Senolysis for Vascular Repair and Immune Microenvironment Reprogramming in the Treatment of Ocular Fundus Neovascularization. Advanced Science. 2026. doi:10.1002/advs.202523495
BibTeX
@article{Zhou2026,
author = {Zhou, Yali and Chen, Tianxing and Liu, Peiyu and Lv, Kangjia and Wang, Yifan and Wang, Xiaoqian and Fang, Junwei and Chen, Chong and Wang, Zhaoyang and Wei, Fang and Xu, Xun},
title = {Dual‐Target ROS‐Driven Spatiotemporal Senolysis for Vascular Repair and Immune Microenvironment Reprogramming in the Treatment of Ocular Fundus Neovascularization},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202523495}
}
EUVIMED